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METHODOLOGY ARTICLE Open Access
Medium throughput bisulfite sequencing
for accurate detection of 5-methylcytosine
and 5-hydroxymethylcytosine
Gary G. Chen1†, Jeffrey A. Gross1†, Pierre-Eric Lutz1†, Kathryn Vaillancourt1, Gilles Maussion1, Alexandre Bramoulle1,
Jean-François Théroux1, Elena S. Gardini2, Ulrike Ehlert2, Geneviève Bourret3, Aurélie Masurel3, Pierre Lepage3,
Naguib Mechawar1, Gustavo Turecki1 and Carl Ernst1*
Abstract
Background: Epigenetic modifications of DNA, such as 5-methylcytosine and 5-hydroxymethycytosine, play important
roles in development and disease. Here, we present a cost-effective and versatile methodology for the analysis of DNA
methylation in targeted genomic regions, which comprises multiplexed, PCR-based preparation of bisulfite DNA
libraries followed by customized MiSeq sequencing.
Results: Using bisulfite and oxidative bisulfite conversion of DNA, we have performed multiplexed targeted
sequencing to analyse several kilobases of genomic DNA in up to 478 samples, and achieved high coverage data
of 5-methylcytosine and 5-hydroxymethycytosine at single-base resolution. Our results demonstrate the ability of this
methodology to detect all levels of cytosine modifications at greater than 100× coverage in large sample sets at low
cost compared to other targeted methods.
Conclusions: This approach can be applied to multiple settings, from candidate gene to clinical studies, and
is especially useful for validation of differentially methylated or hydroxymethylated regions following whole-
genome analyses.
Keywords: Targeted bisulfite sequencing, 5-methylcytosine, 5-hydroxymethylcytosine, Next-generation
sequencing, Customized MiSeq sequencing, Multiplexed PCR-directed BS-amplicons, Multiplexed barcoding of
target amplicon libraries
Background
Epigenetic modifications have been associated with many
aspects of mammalian development and physiology [1, 2].
In particular, the most widely studied epigenetic marks
have been DNA cytosine modifications, namely 5-
methylcytosine (5mC) and 5-hydroxymethylcytosine
(5hmC). Currently, achieving high-resolution, genome-
wide detection of cytosine modifications in sufficient
sample sizes to make claims about disease association
at affordable cost remains a challenge. In mapping
DNA modifications, the most commonly used
technologies include whole genome bisulfite sequencing
(WGBS), which maps cytosine methylation across the en-
tire genome at single base resolution. Although this
method, theoretically, covers every CpG (~30 million) in
the human genome, getting adequate coverage on each in-
dividual CpG site is a costly and formidable task. Another
genome-wide DNA modification methodology, reduced
representation bisulfite sequencing (RRBS) [3, 4], utilizes
methylation-insensitive restriction enzyme digestion and
size selection to reduce the amount of genetic material
being sequenced. Unlike WGBS, RRBS tends to exten-
sively focus on CpG-rich regions [5, 6]. Finally, array-
based technologies are also popular but these are
limited to genomic regions covered by the pre-
selected probes. Still, whether by WGBS, RRBS, or
arrays, genome-wide identification of differentially
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methylated regions (DMRs) often requires a technical
validation and/or replication in additional cohorts,
and deep sequencing of specific target regions is often
called for.
Target validation strategies primarily employ next-
generation sequencing (NGS) of libraries prepared from
target regions from bisulfite-converted (BS) genomic
DNA. The most frequently used library preparation
techniques include, but are not limited to, Illumina’s
TruSeq LT and HT or Nextera technologies, which can
provide precise and accurate measures of DNA modifi-
cations. The TruSeq Custom Amplicon strategy from
Illumina has been recently introduced for amplicon se-
quencing and the interrogation of custom regions of
interest. However, this solution relies on the TruSeq
Custom Amplicon Library Preparation Kit and the use
of their DesignStudio software for designing amplicon
primers, which is not only costly but also limited to the
use of Illumina’s barcoding and sequencing system. The
DesignStudio software generates custom oligonucleotide
panels that are intended for the amplification of genomic
DNA and are not applicable, at this point, to bisulfite-
converted DNA. Therefore, for DNA methylation stud-
ies, one needs to use the TruSeq LT methyl adaptor kit
from Illumina, which is restricted to 12 single indices.
This situation significantly hampers the ability of clinical
and research laboratories to carry out differential methy-
lation analyses in large collections of genomic regions
and sample sets. In addition, these approaches rely on
enzymatic library preparations and remain expensive
and cumbersome to non-experienced users.
Here, we present and characterize a robust approach
for targeted BS-sequencing, which incorporates target
amplification and library generation into three consecu-
tive PCR reactions. Our approach eliminates the need
for expensive amplicon library preparation kits, uses
freely available web-based software for BS-primer design,
and only requires a set of reusable, universal primers for
barcoding, library preparation, and customized sequen-
cing. Our methodology is highly affordable and efficient,
and has been validated, here, in several tissues over mul-
tiple target regions. We show the ability of this approach
to simultaneously interrogate multiple loci in 478 sam-
ples in a single sequencing run. Our unique single bar-
coding system can be easily extended to 1536 indices
and, therefore, outperforms the low-multiplexing and
costly Illumina dual barcoding system. Our method al-
lows users to sequence hundreds of bisulfite or oxidative
bisulfite converted DNA regions ranging from 100 bases
up to several kilobases in a single and customized MiSeq
run. Whether investigating psychiatric phenotypes in
peripheral samples, uniparental disomy in developmental
phenomena, or tumor biopsies in cancer patients, this
methodology will prove valuable as a method to rapidly
and cost-effectively evaluate cytosine modifications in
large sample cohorts and extended genomic regions.
Methods
Subjects
Saliva samples were collected using the Oragene Saliva
self-collection Kit (DNA Genotek, cat. # OG-500) and
stored at room temperature. DNA was extracted using
the prepIT-L2P kit (DNA Genotek, cat. # PT-L2P). Post-
mortem human brain tissue from adult male subjects
was obtained from biorepositories at the Douglas – Bell
Canada Brain Brank. All tissue was dissected at 4 °C,
snap-frozen in liquid nitrogen, and stored at -80 °C
following standard procedures. The Quebec Coroner’s
office assessed the cause of death for each subject and,
subsequently, we obtained information on the subjects’
mental health using psychological autopsies using the
Structured Clinical Interviews for DSM-IV Axis 1. In
addition, brain tissue samples from all subjects were
assessed for absence of pathological processes by a
neuropathologist. Genomic DNA was extracted from
brain tissue using QIAGEN’s QIAmp DNA Mini Kit
(QIAGEN, cat #: 51304). For DNA from saliva and
brain, NanoDrop 2000 spectrophotometer and Quant-
IT PicoGreen (Thermo Scientific, cat. #: P7589) were
used to assess the DNA quality and concentration.
Written informed consent was obtained from next-of-
kin and the Douglas Institute Research Ethics Board
approved this study.
Cell culture
An induced pluripotent stem cell-derived neural pro-
genitor cells (iPSC-NPC) line was generated from skin
cells of a healthy human subject. Lines were stored as
stocks in liquid nitrogen. Cells were grown on poly-l-
ornithine/ laminin coated 6-well plates (Sigma, St. Louis,
MO, USA) and maintained in 70% DMEM, 2% B27, 1%
Penicillin/ Streptomycin (Life Technologies Foster City,
CA, USA), 30% Ham’s F12 (Mediatech Herndon, VA,
USA), with 20 ng/mL bFGF (R&D Systems, Minneapolis,
MN, USA), 20 ng/mL EGF, and 5 μg/mL heparin
(Sigma). To differentiate cells, we removed growth fac-
tors and let cells differentiate for 30 days. Media were
changed every 3 days, whether cells were proliferating or
differentiating. DNA was extracted from collected cells
using QIAGEN’s QIAmp DNA Mini Kit (QIAGEN, cat
#: 51304).
Bisulfite and oxidative bisulfite conversion of human
brain genomic DNA
For standard bisulfite conversion, 500 ng of genomic
DNA from saliva from each individual was bisulfite con-
verted using the EZ-96 DNA Methylation-Gold kit
(Zymo Research, cat. # D5007) and was eluted in 30 μL
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of water. 1ug of DNA from post-mortem brain tissue
was bisulfite converted using QIAGEN’s EpiTect Fast
Bisulfite Kit (QIAGEN, Cat. #: 59104), as per manufac-
turer’s guidelines. Oxidative bisulfite conversion was per-
formed using the CEGX True Methyl kit (Cambridge
Epigenetix, Cat. #: CEGXTMS). Briefly, 1ug of DNA
from all samples was purified and denatured. DNA from
each subject was then split in 2 equal reactions, one of
which underwent chemical oxidation followed by bisul-
fite conversion, while the other underwent mock oxida-
tion (oxidant replaced by water) followed by bisulfite
conversion. All bisulfite reactions were cleaned-up using
bead-based purification and final elution was in 30ul of
elution buffer. Efficiency of oxidation and bisulfite con-
version using the CEGX True Methyl kit were evaluated
pre- and post-sequencing using spike-in controls, as per
manufacturer’s guidelines.
Targeted-BS sequencing: PCR amplification, library
preparation, and customized sequencing
Primer design
Bisulfite sequencing primers were designed for each target of
interest using the Methyl Primer Express software v1.0 from
ThermoFisher Scientific (https://www.thermofisher.com/
order/catalog/product/4376041). We designed primers for
the first round of PCR without any modifications,
adapters, or indices. Optimal amplicon length, espe-
cially for oxidative bisulfite sequencing, is 200–300 bp.
Amplicon lengths for standard bisulfite conversion for
methylation analysis were always less 500 bp to allow
for the interrogation of the entire amplicon with high
quality scores using 300 bp paired-end sequencing. Al-
though CpGs in the primer sequence were avoided,
cytosines in a CpG context in the forward and reverse
primers that could not be avoided were replaced with
Ys (50% mix of cytosine and thymine) and Rs (50% mix
of adenine and guanine), respectively. For the 2nd round
PCR primer sets, we designed primers identically to
round 1 primers but added universal 22-bp overhangs
(CS1 and CS2) on the 5` forward primer and 3`reverse
primers, respectively. The CS1 sequence serves as an
annealing site for the Read1 customized sequencing
primer (LNA-CS1) and CS2 serves as an annealing site
for both the Read2 customized sequencing primer
(LNA-CS2) and the Index read primer (LNA-CS2rc).
When designing primers carrying the CS1 or CS2 se-
quences, we added three N bases (25% mix of all four
bases) between the CS and target sequences to increase
base diversity and improve sequencing QC in the early
cycle stages. A third pair of PCR primers, for round 3,
was designed to add Illumina flow-cell attachment sites
(P5 and P7) and a unique 10 base-long non-Illumina
single barcode. We used Fluidigm-based barcodes for
the first 384 indices (Fluidigm Corporation, California,
USA) and our home-made barcodes for beyond 384 in-
dices. These primer sequences targeting specific loci,
the CS1, CS2, P5, and P7 adaptor sequences, the indi-
ces, and the LNA oligonucleotide sequences can be
found in Additional files 1, 2, 3 and 4.
Library preparation
Figure 1 shows the complete work flow of our library
preparation method. An initial PCR reaction was per-
formed on bisulfite or oxidative bisulfite converted DNA
using the KAPA HiFi Uracil + ReadyMix (Kapa Biosys-
tems, cat. #: KK2802) and all round 1 bisulfite primer
sets, for all targeted regions, in a single reaction per sub-
ject. The first PCR for target amplicon generation used
the following thermal cycler condition: 95 °C for 3 min,
then 38–48cycles of 98 °C for 20s, Tm (60 °C in most
cases for multiplexed primer sets) for 15 s, and 72 °C for
15 s, then finished with 72 °C for 30 s. Next, we per-
formed two rounds of purification using Agencourt
AMPure XP beads (AMPure) (Beckman Coulter, Cat.
#: A63881). We used a 1× AMPure ratio (1:1 AMPure
to PCR product) for PCR products for all rounds of
PCR. The second round of PCR was performed under
the same thermal cycler conditions, but with only 10 cy-
cles. The purpose of the 2nd round of PCR is to add the
CS1 and CS2 sequences to each amplicon. While this
can, conceivably, be done in Round 1 of PCR, we have
much better amplification of targeted regions when the
initial PCR includes only primers targeted to the bisulfite
converted genome. We also use `non- Uracil + ` KAPA
HiFi ReadyMix (Kapa Biosystems, cat. #: KK2602) in PCR
Round 2 to reduce costs. The PCR reaction was purified
twice with AMPure beads, as performed following Round
1 PCR. Finally, the third PCR reaction with another 10 cy-
cles was performed using the 5` universal primer and 3`
barcoding primer sets to add the Illumina flow-cell at-
tachment sequence P5 and P7, as well as single unique
barcode. A more detailed description of the universal
CS1, CS2, P5, and P7 adaptor additions can be found in
Additional file 5. Two double-sided AMpure purifica-
tions were performed to complete the library prepar-
ation for complete removal of non-purity and primer
dimers. Libraries were quantified using the Agilent
2200 TapeStation Instrument and DNA 1000 reagents.
Next, we pooled all normalized libraries from all sam-
ples into a single reaction tube for sequencing.
Custom MiSeq sequencing
To achieve an optimal cluster density of 700–800 K/
mm2 for bisulfite-sequencing on the Illumina MiSeq, a
final molarity of 2 nm of the pooled samples was used.
A 10–20% PhiX spike-in was also included to increase
total base diversity, which is essential for obtaining high
quality reads during bisulfite sequencing. The PhiX
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spike-in may need to be further increased if one is se-
quencing a single region in very large sample sets.
Pooled samples were sequenced on the Illumina MiSeq
sequencer using the V3 600 cycle kit to perform a
300 bp paired-end sequencing run. For customized
MiSeq sequencing, three customized sequencing
primers, LNA-CS1 (Read1), LNA-CS2rc (Index Read-
ing), and LNA-CS2 (Read2) primers corresponding to
Illumina read1, index, and read2 sequencing primers,
respectively, were synthesized in locked nucleic acid
form (EXIQON, primer sequences listed in Additional
file 2) and loaded onto the corresponding sites on the
MiSeq reagent cartridge (see Additional file 6). Illumina
Experiment Manager (EM) does not support custom-
ized sample running sheet, so an example of a custom-
ized sample running sheet in .csv format was created.
An example of the .csv sample running sheet is also
available in Additional file 7.
NEXTERA XT library preparation
Libraries were prepared using the NEXTERA XT kit
(Illumina, Cat. #: FC-131-1024), as described by Masser
et al [7]. Briefly, dual-indexed libraries were generated
according to the manufacturer’s protocol. Initial PCRs
were performed on bisulfite converted DNA using a Pro-
Flex thermocycler, under the following conditions: 95 °C
for 3 min, then 45 cycles of 98 °C for 20s, 58 to 62°c (de-
pending on the primer pair used) for 15 s, and 72 °C for
15 s, and finished with 72 °C for 1 min. Purified PCR
products were quantified by Quant-IT Picogreen
(Thermo Scientific, cat. #: P7589) and pooled to a final
0.2 ng/μl concentration. A total of 1 ng was used for
library generation in a 96-well plate format.
Transposome-mediated simultaneous DNA fragmenta-
tion and adapter ligation, that is, tagmentation, was per-
formed at 55 °C for 5 min. After the tagmentation
reaction, indexing specific PCR primers were added two
per well for unique dual indexing. A 12-cycle PCR was
performed to amplify the libraries and incorporate the
index sequences to the libraries using the following reac-
tion conditions: 72 °C for 3 min and 95 °C for 30s, then
11 cycles of 95 °C for 10s, 55 °C for 30s, and 72 °C for
30s, and finished with 72 °C for 5 min and hold at 10 °C.
Amplified libraries were purified using 30 to 50 μl
AMPure XP beads (Beckman-Coulter, Brea, CA, USA),
and eluted off the beads in 52.5 μl resuspension buffer
(provided with Nextera XT). The quality of double-
stranded libraries was checked using a High Sensitivity
Fig. 1 Targeted BS-Seq library preparation requires 3 consecutive PCR reactions. Three successive steps for preparation of targeted BS-Seq libraries
include the initial amplification of the loci of interest, the addition of the CS1 and CS2 universal adaptors, and the inclusion of the P5 and P7
adaptors that allow for cluster formation on the flow cell
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DNA chip run on the Agilent 2100 Bioanalyzer (Agilent
Technologies, cat. #: 5067-4626) for size and molarity
determination. Based on these metrics, libraries were
diluted to 2nM in 10 mM Tris with 0.5% Tween. Equi-
molar libraries were pooled in equal volumes for de-
naturation and dilution in HT1 (Illumina, San Diego,
CA, USA) buffer. Briefly, 10 μl of pooled NGS library
was mixed with 10 μl 0.2 N NaOH for 5 min, then the
library was diluted to 20 pM in HT1 buffer. PhiX control
libraries were used to increase diversity of base calling
during sequencing. 10 nM stock of PhiX library was de-
natured in 0.2 N NaOH, then diluted to 20 pM in HT1
buffer. Diluted, multiplexed libraries were mixed with di-
luted PhiX at 4:1 volume ratios, followed by a final dilu-
tion to 11pM with HT1 buffer (1 ml final volume).
600 μl was loaded onto the reagent cartridge for MiSeq
sequencing. In contrast with the aforementioned
Targeted-BS sequencing approach, here classical Illu-
mina sequencing primers were used.
Reduced Representation Bisulfite Sequencing (RRBS)
RRBS was performed as described previously [8, 9].
Briefly, genomic DNA was extracted from iPSC-NPCs
(D28) and digested with MspI. Fragments were end-
repaired, Illumina adaptor sequences were ligated, and
the libraries were bisulfite converted using Qiagen’s
EpiTect Fast 96 Bisulfite Kit. Sequencing was per-
formed on Illumina’s HiSeq 2000 using 50 bp single-
end reads. Only CpG sites with coverage greater than
5× were included in the analyses.
Bioinformatic and statistical analyses
Adaptor sequences were trimmed from the reads when
encountered (using Trimmomatic 0.35 with the following
parameters: ILLUMINACLIP:Fluidigm_primers.fa:3:30:9
HEADCROP:3 LEADING:20 TRAILING:20 SLIDING-
WINDOW:4:20 MINLEN:50, Fluidigm_primers.fa con-
taining the primers). The sequencing reads with a Phred
quality score less than 20 were discarded. Bis-
mark v0.14.4 was used to align the remaining reads to the
target regions. Bismark was run using Bowtie 2 (version
2.1.0). The extraction of the number of unconverted and
converted CpGs for each cytosine was done with the
script bismark_methylation_extractor provided with
Bismark with the following parameters: -p –no_overlap
–cytosine_report –counts -s –bedGraph. The unconverted
CpG percentage was calculated for each CpG site as un-
converted read counts divided by total read counts. 5hmC
percentage at each CpG site was derived as unconverted
CpG ratio in bisulfite-only reaction subtracted by the
counterpart in oxidation + bisulfite reaction of the same
DNA sample.
Results
Comparison of targeted BS-sequencing with Nextera XT
We performed target amplification using bisulfite con-
verted DNA (BS-DNA) from post-mortem brain tissue
of 16 healthy controls across genomic regions with vary-
ing levels of cytosine modifications, as determined from
previous genome-wide methylation mapping studies
performed in our laboratory. In total, there were three
primer sets used in this experiment targeting different
regions of the human OPRK1 gene (see primers se-
quences in Additional file 3). BS-DNA amplicons were
then used for library preparation with either NEXTERA
XT or our newly developed targeted BS-Seq approach.
In case of NEXTERA XT, samples were pooled with
10–15% PhiX to increase base diversity in the sequen-
cing reaction and analysed on the MiSeq using Illumina
sequencing primers and indices. The run, which pooled
multiple experiments not described here, produced 11.8
million reads. A total of 1.64 million reads were attrib-
uted to the 16 indices (samples) of interest, among
which 0.96 million reads passed filtering. 88.26 ± 0.78%
of those reads were aligned to the reference human
genome. The percent of reads allocated to each of the
16 samples ranged from 3.47 to 10.03%, slightly deviat-
ing from the expected 6.25% per sample because of pip-
etting variability during pooling. Across all samples, the
average read number per locus was 66,526 ± 4825,
19,580 ± 1697, and 14,397 ± 1207, which likely reflects
the variable efficiency of primer pairs during PCR
amplification.
In case of the targeted BS-Seq approach, we con-
firmed the quality of library preparation by showing the
size shifts indicating the successive inclusions of CS1/
CS2 sequences (PCR Round 2) and Illumina’s P5 and
P7 flow-cell attachment sequences (PCR Round 3)
(Fig. 2a). The pooled samples contained a 10–15% PhiX
spike-in, and this run, which pooled additional experi-
ments not described here, produced 182,195 reads that
were attributed to the 16 indices (samples) of interest,
with 147,010 reads passing filtering. The percentage of
reads allocated to each of the 16 samples ranged from
3.49 to 15.94%, with a slight deviation from the ex-
pected 6.25% similar to the one described above for
NEXTERA. Across all samples, the average read num-
ber per locus was 1099 ± 130, 469 ± 62, and 1782 ± 222,
reflecting the variability in primer pairs efficiencies dur-
ing PCR amplification. Considering that each CpG is
covered >100×, this does not affect final percent methy-
lation calling.
Among limitations associated with the NEXTERA XT
approach is the possibility that coverage within targeted
regions may be uneven due to the variable efficiency of
transposomes to access and cut DNA regions with dif-
ferent base content, as well as decreasing coverage at the
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extremities of targeted PCR amplicons [10, 11]. Our data
using NEXTERA XT are consistent with these notions,
as coverage was significantly lower at both ends of each
amplicon (Fig. 2b-d), and a small region covering four
CpG sites within one amplicon (Fig. 2d) also showed
low coverage. In our targeted BS-Seq approach, since
every read for a given amplicon starts and ends at simi-
lar positions in the reference genome, we observed
much more stable coverage, with only a modest drop at
the center of two amplicons (Fig. 2c-d) that, as expected,
a
b c d
e f
Fig. 2 Targeted BS-Seq performs to the same standard as Illumina’s NEXTERA XT kit. Three genomic regions located in the human OPRK1 gene
were amplified by quantitative PCR and then used for library preparation with either (i) the commercially available, gold standard NEXTERA XT kit
(Illumina) or (ii) our targeted BS-Seq approach. a In targeted BS-Seq, successive rounds of PCR are performed to amplify BS-DNA and add universal
and reusable primers (CS1 and CS2), followed by adapters to the MiSeq flow cell (P5 and P7 + index). Gel electrophoresis was performed on
Agilent’s Tape Station and shows the expected increases in size of PCR products for 2 replicates after each round of PCR. b–d Both NEXTERA
XT and targeted BS-Seq yielded very high coverages throughout the amplicons of interest, with the exception of 4 CpG sites in NEXTERA XT
results (c, d). Note that while the difference in coverage between the 2 methods only reflects the amount of material loaded onto the sequencer, the
targeted BS-Seq method allows for a more even distribution of coverage along the amplicons and lower variability in coverage across biological
samples. Values represent mean ± S.E.M. e NEXTERA XT (y-axis) and targeted BS-Seq (x-axis) measured very similar DNA modification levels at
all CpGs interogated (r2 = 0.9947, p < 0.0001), confirming that our methodology matches a gold standard, commercially available solution to
call DNA modifications with high precision. f This correlation remains highly significant (r2 = 0.7476, p = 0.0012) even when looking at the 10
CG sites that showed intermediate methylation levels, corresponding to sites with more variable methylation states across individual cells
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reflected a drop in Phred quality scores at the extrem-
ities of long reads obtained from BS-converted DNA.
Of the 83 CpGs targeted by the three primer sets at
these loci, including the four CpGs with lower cover-
age, cytosine modification values ranged from 0 to
100% (Fig. 2e), and methylation levels were detected
almost identically between our approach and Nextera
(r2 = 0.9947, p < 0.0001). Furthermore, this correlation
remains strong when looking specifically at the 10
more variable sites (r2 = 0.7476, p = 0.0012) (Fig. 2f ).
We note also that these strikingly similar results were
obtained while very distinct coverages were observed
across the two methods, which simply reflect the dif-
ferent concentrations of pooled samples loaded onto
the MiSeq cartridge. In addition to this comparison
with NEXTERA, and as an additional cross-validation
of our methodology with alternative technologies, we
present, in Fig. 3 (see below), results from the com-
parison of DNA methylation measures obtained using
RRBS and targeted BS-Seq.
Altogether, results strongly suggest that high precision
measures of cytosine modifications can be achieved in
much higher sample numbers, even in the face of de-
creasing coverage, as discussed below. Overall, these re-
sults confirm the efficacy of our targeted BS-Seq
approach to analyze a range of modification levels, with-
out the associated costs and experimental difficulties of
traditional, enzyme-based library preparations.
Fig. 3 Multiplexed single-barcode system for targeted BS-Seq can accommodate a variety of strategies and can be extended to 478 individual
indices. Total reads per index are outputed following each MiSeq run. a Using a smaller sample size, we are able to generate data where the
percentage of reads allocated to each index is consistent and abundant. b Pooling indices with different ratios allows users to control the percent-
age of reads allocated to individual indices. c-d Our targeted BS-Seq protocol and the MiSeq sequencer can accommodate an extended number of
indices, beyond 300 (c) and 478 (d), while still maintaining coverage greater than our threshold of 100×. a-d Y-axes correspond to the % of
reads identified per indexed subject after sequencing. X-axes correspond to the number of indexed samples loaded onto the MiSeq. e Representative
diagram of tiled primers on positive and negative strands of 11 loci interrogated by targeted BS-Seq, shown here for the CAMK2B locus as an illustration.
These 11 loci were located on the following 7 genes: CAMK2B (1 locus), PAX6 (4), NDRG2 (2), LHX1 (1), ATP1A3 (1), TBR1 (1), and OTP (1). f Correlation of
% modification values obtained using RRBS or our targeted BS-Seq approach (r2 = 0.7922, p = 0.0002). The % of modification correspond to the mean
values obtained across three biological replicates for both RRBS and targeted BS-Seq
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Medium throughput capabilities of this targeted
approach
We next determined the multiplexing capacity of this
targeted approach. To do so, we analyzed cytosine modi-
fication levels in progressively larger sample sizes with
varying number of loci being targeted. First, we used
fewer samples to allow for increased coverage per loci in
each sample. This run interrogated 26 loci in post-
mortem human brain from 54 subjects and included a
15% PhiX spike-in. In total, 16.05 million reads passed a
Phred QC score > 30, representing 78.0% of the total
reads. We are able to show equal distribution of cover-
age across samples, with 1–2% of all reads being allotted
to each index (Fig. 3a). In a second test, we demonstrate
the ability of this method to use different pooling ratios
for two different projects, as well as sequencing controls,
negative controls, and a 20% PhiX spike-in (Fig. 3b). The
first project contained amplicons for seven genomic loci
across 96 samples, which required four times higher se-
quencing depth than the second project that investigated
three loci across 40 samples. Four sequencing controls
for the second project were also included in this run,
and were included at a 4× dilution relative to the sam-
ples of the second project. In total, 14.05 million reads
passed a Phred QC score > 30, representing 78.7% of the
total reads. These data confirm the ability of this meth-
odology to accurately sequence libraries from multiple
projects during the same MiSeq sequencing run, thereby
adding to the cost savings.
To further test the utility of this methodology in large
cohorts, we attempted to pool 288 and then 478 individ-
ual indices in a single run. Both runs interrogated four
genomic loci in human saliva samples, the first with a
10% PhiX spike-in and the second with 20% PhiX. Al-
though the output per sample is lower, as expected,
the crowded flow-cells still generated greater than 85.9
and 74.1% of reads that passed a Phred QC filtering
score > 30, respectively, and a minimum coverage of
100× per loci (Fig. 3c and d). When using larger co-
horts, equimolar pooling is more challenging because
accurate quantification of each sample can be costly.
Nevertheless, the minimum coverage was still ob-
tained, even with the larger variance in the percent of
reads per sample seen in Fig. 3d. This experiment
highlights the ability of this approach to multiplex up-
wards of 478 indices and many primer sets in a single
reaction, targeting all genomic regions of interest at
once.
In an attempt to decrease bench time, we also wanted
to determine the extent to which primers targeting dif-
ferent loci can be multiplexed during the first round of
PCR. In this run, we designed ~16 primers (8 on each of
the positive and negative strands), both with and without
the CS1 and CS2 sequences included, across 14 loci in
12 samples (Fig. 3e). All 236 primers, corresponding to
multiple potential amplicons for each locus, were multi-
plexed in a single PCR reaction, per sample, to amplify
bisulfite converted DNA from iPSC-NPC lines, which
was followed by the second and third rounds of PCR to
include the CS1/CS2 and P5/P7 sequencing adaptors, re-
spectively. The sequencing run generated 21.7 million
reads that passed a Phred QC filtering score > 30 (82.7%
of total reads), of which 8.3 million were specific to this
project. Each of the 12 indices received between 2.0 and
4.7% of reads that passed filtering (mean = 3.20 ± 0.24%),
which is quite close to the expected 3.45% per sample).
Impressively, 12 of the 14 loci were successfully ampli-
fied and sequenced, which included data from 702 CpGs
across 10 kb of DNA. Coverage ranged from 200 to
20,000×, depending on the locus, with a mean of 6771 ±
2132× (Table 1). This range is likely due to the different
primer efficiencies in the multiplexed reaction. Although
this should be taken into consideration when designing
an experiment, having reached a minimum of 100×
coverage across all loci confirms the efficacy of this
methodology even in such a high multiplexing scenario.
Finally, for three of the samples interrogated during
the latter highly multiplexed run, DNA methylation
measurements were already available from previous
RRBS experiments (conducted by our group in the
context of studies investigating DNA methylation
changes during iPSC-NPC differentiation). Results
show that a significant correlation was observed be-
tween the % modification from RRBS and % modifica-
tion from our targeted sequencing approach across
these loci (r2 = 0.7922, p = 0.0002, see Fig. 3f ), demon-
strating the comparability of our approach to a restric-
tion enzyme-based library preparation methodology.
Target validation using oxidative bisulfite
sequencing (oxBS)
Recent studies have uncovered 5hmC as a new, stable
epigenetic mark [12–14] that, in contrast with the
negative effect classically associated with 5mc, posi-
tively affects gene expression, at least in brain tissue
[15–17] and immune cells [18]. Because bisulfite treat-
ment can convert both 5hmc and 5mc [19], we assessed
whether our targeted BS-Seq method could differenti-
ate 5mC from 5hmC. To distinguish 5hmc and 5mc, a
chemical or enzymatic oxidation prior to bisulfite con-
version is required when analysing DNA [20, 21]. To
determine if our approach can also be used to evaluate
5hmc, we performed oxidative (ox) BS, a specific chem-
ical oxidation of 5hmC to 5fC, prior to bisulfite treat-
ment. The purpose of this oxidation step is to generate
5fC, which is no longer resistant to bisulfite-mediated
C-T conversion [22]. First, we confirmed the efficiency
of the oxidation and bisulfite reactions by digesting
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specialized spike-in sequences with known 5hmC at an
enzymatic cut site. The TCGA Taq α1 cut site in these
spike-in sequences contain a 5hmC at the cytosine pos-
ition. The combination of the oxidation reaction and
the bisulfite conversion will convert 5hmC to thymine
and prevent the enzyme from cutting, while the bisul-
fite reaction alone will maintain this cut site (Fig. 4a).
Results from this experiment demonstrate that our
technical procedures work as anticipated with a known
standard. To test this procedure on a real example, we
used DNA from post-mortem brain tissue of 19 psychi-
atrically healthy individuals, targeted seven genomic
loci for 5hmC and 5mC mapping, and proceeded with
the medium throughput protocol (primer sequences
can be found in Additional file 4). Following library
preparation, we confirmed the addition of the universal
primer sequences and indices, as illustrated by the ex-
pected increase in molecular weights of our amplicons
(Fig. 4b). Following sequencing, we first assessed the
cytosine to thymine conversion rates to confirm the ef-
ficacies of the oxidation and bisulfite reactions we ob-
served prior to sequencing. In the oxidation reaction,
we observe a near complete conversion of 5hmC bases
to thymine, while this is abolished in the bisulfite-alone
reaction (Fig. 4c).
The sequencing run, which included 94 indices from
two different experiments, produced 26.7 million reads
passing a Phred QC score greater than 30. Of these, 11.5
million reads were allotted to the 38 indices (mean reads
per index = 301,350 ± 5883), which corresponded to the
oxBS and BS fractions from the 19 samples used in this
manuscript, and covered 30 CpGs across the seven tar-
geted genomic regions of interest. Using a representative
group of CpGs, chosen based on having varying levels of
5mC and 5hmC between 0 and 100%, we detect a range
of 20–100% 5mC and 0–60% 5hmC levels with little
variation across subjects (Fig. 4d), suggesting good in-
ternal consistency across samples. Furthermore, we
assessed the distribution of both 5mC and 5hmC levels
across the all the loci we investigated and show an in-
verse relationship between 5mC and 5hmC (Fig. 4e),
which could be expected given their relationship to one
another. These data confirm the extended use of our tar-
geted validation approach to effectively analyse 5hmC
following chemical oxidation.
Discussion and Conclusions
The goal of the present study was to implement a
medium throughput methodology to interrogate DNA
methylation and hydroxymethylation in multiple bio-
logical samples and genomic regions in a cost-effective
and timely way. First, we compared the proposed tar-
geted BS-Seq methodology with a commercially available
gold-standard, in this case the NEXTERA XT kit, and
showed that both methods yield high-coverage data and
very similar levels of DNA cytosine modifications. We,
then, extended the utility of this methodology to simul-
taneously sequence up to 478 individual indices in a sin-
gle MiSeq run. Finally, we confirmed the ability of this
targeted BS-Seq method to be combined with oxBS-Seq
to differentiate 5mC from 5hmC in genomic DNA.
In this study, we used the NEXTERA XT approach as
a point of comparison to determine the efficacy of our
methodology. NEXTERA XT is an excellent and widely
used library preparation kit because it allows for the pro-
cessing of large amplicons, up to several kb according to
manufacturer. However, not only does the bisulfite con-
version step lead to fragmentation of the input DNA
template, making it difficult to PCR amplify fragments
larger than 500 bp, but incomplete cytosine to thymine
conversion rates are higher for longer amplicons [23].
As such, the ability to maximize the potential of library
Table 1 Quantitative output from highly multiplexed targeted BS MiSeq run
Chromosome Covered region Length of the
covered region (bp)
Number of CpG sites detected
in covered region
Coverage full data set Number of primer pairs
Chr4 46,391,588–46,392,165 578 44 5407 10
Chr3 11,034,244–11,035,166 923 90 19,607 7
Chr7 44,349,021–44,349,856 836 62 21,495 8
Chr11 31,820,209–31,820,665 457 26 1799 8
Chr11 31,825,606–31,827,393 1788 110 8232 16
Chr14 21,542,358–21,543,245 888 29 194 8
Chr14 21,558,269–21,559,093 825 49 3117 7
Chr17 35,299,547–35,300,293 747 61 1365 10
Chr19 42,489,794–42,490,445 652 16 5089 7
Chr20 61,992,854–61,993,598 745 53 1830 7
Chr2 162,284,277–162,284,993 717 58 369 7
Chr5 76,925,266–76,926,368 1103 104 12,744 8
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preparation technologies for cytosine modification ana-
lyses, which could potentially accommodate longer DNA
amplicons (such as Nextera XT), is greatly reduced.
Similarly, although Illumina’s V3 MiSeq kit allows for
600 cycles, the current technology generates the best
quality reads for first 200–250 bases. For these reasons,
the optimal bisulfite-PCR amplicon length should be re-
stricted to a maximum of 500 bp. For targeted regions
greater than 500 bp, creating tiled primer pairs allows
for the interrogation of the entire region of interest.
Therefore, while the NEXTERA XT kit is a feasible solu-
tion, we have produced data of similar quality at a much
lower price using a targeted BS-Seq approach.
The strength of this method is the high level of muti-
plexing built into the primer design and the ability to
index hundreds of samples on a single reaction of a
a
c
d e
b
Fig. 4 Targeted oxBS accurately differentiates 5mC from 5hmC in post-mortem brain. a A 100 bp spike-in digestion control sequence contains a
5hmC mark at the TCGA Taq α1 restriction enzyme digestion site located at position 42 (hC). An efficient oxidation reaction will convert this
5hmC to thymine after bisulfite conversion, which will prevent the enzyme from cutting (T in the oxBS arm). In the bisulfite-alone reaction, the
5hmC will remain a cytosine after the bisulfite reaction and will be cut by the enzyme (C in the BS arm). As per manufacturer’s guidelines,
digestion control reactions were run on a 1.5% agarose gel with (+) and without (-) the restriction enzyme and an additional cutting control was
included, also with (+) and without (-) the restriction enzyme. b The targeted bisulfite sequencing approach presented in this manuscript involves
consecutive PCR reactions to add the universal adaptors and indices, therefore, we expected to see an increase the size of the amplicons. Gel
electrophoresis was performed on Agilent’s Tape Station. Each lane represents a different subject. In the red box, the 3rd and 4th bands represent
amplicons with the universal adaptors, while the 1st and 2nd bands include the universal adaptors and the indices. c During the target amplification,
primers were also designed to interrogate spiked-in sequencing controls that contain a variety of 5hmC, 5mC, 5fC, and C bases (provided by
manufacturer). Conversion rates of cytosine to thymine in the oxBS (left) and BS (right) reactions were as expected, with 5hmC being converted
to thymine after oxidation and bisulfite conversion. d Representative CpGs showing varying levels of 5mC and 5hmC between 0 and 100%
were selected to design a standard curve showing the range of detection of 5hmC and 5mC in the loci we interrogated. e The correlation of
%5mC and %5hmC across all 30 CpGs shows an inverse relationship between the two modifications
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benchtop sequencer. Currently, targeted cytosine modifi-
cation mapping requires time-consuming primer design
and primer assessment to ensure accurate amplification.
We have circumvented this problem by using many pri-
mer sets for a given locus combined with parallel se-
quencing of amplicons. While more primer sets virtually
guarantee off-target effects, they also act in unexpected
ways at the target region to maximize the coverage. We
have demonstrated, in this study, that this multiplex-
ing can also work across multiple regions in the same
reaction tube. While this leads to more off-target ef-
fects, we show that average coverage is still above the
100× threshold for regions of interest, and the down-
stream bioinformatic processing remains the same
since non-target regions can be discarded. Further-
more, the simultaneous amplification of multiple tar-
gets using multiplexed primer sets in a single PCR
reaction can save input BS-DNA. This is especially im-
portant in certain clinical or experimental cases where
input DNA is scarce.
The increased customized index capacity for multiple
target amplicons and, importantly, the possibility to dif-
ferentiate 5mC and 5hmC provides strength to the val-
idity and usefulness of our methodology, and shows
several clear advantages over other commercially-
available library preparation and indexing systems. In
particular, this method does not require expensive
methylated primers or oligonucleotides. Furthermore,
while we show, in the present manuscript, the feasibil-
ity of interrogating up to 478 samples using our 10 nu-
cleotide single barcoding system, the maximal capacity
could be mathematically expanded to 1536 indexes. To
achieve this same level of multiplexing using commer-
cial kits, one would need to buy multiple sets of each
indexing system, which drastically increases the associ-
ated costs. Although increasing the number of indices
in a single run will inherently decrease the coverage per
loci, this minor limitation can be easily overcome by
running a second MiSeq reaction, which is still less ex-
pensive than using other library preparation kits.
Current methodologies for bisulfite sequencing are
performed on the whole genome, such as WGBS, or
on a representative fraction, such as RRBS. However,
the accessibility of the sequencing technologies
remains limited because they require exhaustive se-
quencing to achieve sufficient coverage. As such, ex-
ploratory experiments are being conducted on small
sample sizes, and often yield results based on coverage
less than 10×. Here, we present a methodology that
will allow researchers to validate WGBS or RRBS find-
ings in an extended sample size at a reasonable cost,
while ensuring sufficient coverage.
This technology is not only suitable as a validation
tool, but it can also serve for additional needs, from
candidate gene studies to clinical diagnostic procedures.
In candidate genes studies, numerous genomic regions
can be analyzed simultaneously by pooling multiple PCR
products across large sample sizes. In clinical settings,
high-resolution data about cytosine modifications, in-
cluding non-CpG methylation, can be collected while re-
ducing the cost of NGS approaches. In its entirety, the
combination of our BS-Seq library preparation method
with next-generation sequencing on Illumina’s MiSeq
benchtop sequencer represents the ideal platform for
studying cytosine modifications, regardless of phenotype
or field of study.
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Additional file 1: Sequences of universal primers and indices used to
achieve the multiplexing of up to 478 samples. (XLSX 9 kb)
Additional file 2: LNA oligonucleotides used for customized
sequencing on the MiSeq platform. (XLSX 8 kb)
Additional file 3: Primers used for amplification of genomic DNA using
NEXTERA XT and targeted BS-Seq (Fig. 3). (XLSX 9 kb)
Additional file 4: Primers used for amplification of genomic DNA in
oxBS experiments (Fig. 4). (XLSX 10 kb)
Additional file 5: Further to the information provided in Fig. 1,
Additional Figure S1 provides additional details regarding the CS1, CS2,
P5, and P7 primer sequences, as well as the location of the barcode.
(PPTX 144 kb)
Additional file 6: Using this customized BS-Seq method requires users
to modify the sequencing reagent cartridge provided by Illumina. These
are the operational steps for performing customized MiSeq sequencing
run with customized sequencing primers (CS1, CS2, and CS2rc). Arrows
indicate the transferring of fluid from fro one tube number to another on
Illumina’s reagent cartridge. (1) The contents of tube 12 should be placed
in tube 18. (2) The contents of tube 13 should be placed in tube 19. (3)
The contents of tube 14 should be placed in tube 20. (PPTX 1142 kb)
Additional file 7: csv sample running sheet. (CSV 19 kb)
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